findmyKOL
Clinical trialNCT07162363Not, yet, recruitingPhase 2/PHASE3Interventional

Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

SponsorUniversity of Illinois at ChicagoEnrollment240ICH - Intracerebral HemorrhageIntracerebral Hemorrhage
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicenter, randomized, open-label trial designed to evaluate the safety, feasibility, and efficacy of combining minimally invasive surgery (MIS) with intravenous deferoxamine (DFX) for the treatment of spontaneous intracerebral hemorrhage (ICH), compared to standard medical care. This trial represents the first investigation of a dual-modality approach in ICH, integrating mechanical clot evacuation with biochemical neuroprotection, with the goal of improving neurological outcomes.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Gursant S. Atwal, MD

    University of Illinois Hospital & Health Sciences System (UI Health)

    Principal Investigator
    clinicaltrials.gov ↗
  • Javed Iqbal, MBBS

    University of Illinois Hospital & Health Sciences System (UI Health)

    Study Director
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Illinois Hospital & Health Sciences System (ui Health)

    Chicago, Illinois, United States

    Gursant S. Atwal, MDJaved Iqbal, MBBS

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Deferoxamine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Mar 2026
Primary completion
30 Dec 2028
Completion
30 Dec 2028
Last update posted
10 Oct 2025
Registered enrollment
240
Registry id
NCT07162363
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.